Zacks Investment Research on MSN3h
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...
The Woodlands-based company strikes obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
Houston-area company may be developing next hot weight-loss drug
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HilleVax, Inc (HLVX), Lexicon Pharmaceuticals (LXRX) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...
Explore more
American Association of Individual Investors2d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 25.32%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...
Fierce Biotech5d
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Lexicon Pharmaceuticals’ (LXRX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals
In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...
Swiss National Bank Grows Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th ...